Key Dates

Related Announcements

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional).

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PAR-19-368, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)."

Parts 1 and 2 of PAR-19-368 now contain NCI-specific information (only as shown below) to reflect NCI's participation in this funding opportunity announcement.

A. Part 1. Overview Information modified (by this notice) to read (in italics):

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Cancer Institute (NCI)

B. Part 2. Section VII. Agency Contacts modified (by this notice) to read (in italics):

Scientific/Research Contact(s)

Marsha F. Lopez, Ph.D., M.H.S.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: [email protected]

I-Jen Castle, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-827-4406
Email: [email protected]

Carolyn Reyes-Guzman, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-7244
Email: [email protected]

Financial/Grants Management Contact(s)

Jennifer L. Schermerhorn
National Institute on Drug Abuse (NIDA)
Telephone: 240-631-2090
Email: [email protected]

Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4704
Email: [email protected]

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]

NOTE: All other aspects of PAR-19-368 remain unchanged.

Inquiries

Please direct all inquiries to:

Carolyn Reyes-Guzman, Ph.D., M.P.H.,
National Cancer Institute (NCI)
Telephone: 240-276-7244
Email: [email protected]